|
🐜
|
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.
16 auth.
M. Oshima,
B. Neuen,
Jingwei Li,
V. Perkovic,
D. Charytan,
D. de Zeeuw,
Robert Edwards,
T. Greene,
A. Levin,
K. Mahaffey,
...
L. De Nicola,
C. Pollock,
N. Rosenthal,
D. Wheeler,
M. Jardine,
H. Heerspink
|
6 |
2020 |
6
🐜
|
|
🦁
|
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
11 auth.
Jingwei Li,
M. Woodward,
V. Perkovic,
G. Figtree,
H. Heerspink,
K. Mahaffey,
...
D. de Zeeuw,
F. Vercruysse,
Wayne Shaw,
D. Matthews,
B. Neal
|
6 |
2020 |
6
🦁
|
|
🐜
|
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.
19 auth.
C. Cannon,
V. Perkovic,
R. Agarwal,
J. Baldassarre,
G. Bakris,
D. Charytan,
D. de Zeeuw,
Robert Edwards,
T. Greene,
H. Heerspink,
...
M. Jardine,
A. Levin,
Jingwei Li,
B. Neal,
C. Pollock,
D. Wheeler,
Hong Zhang,
B. Zinman,
K. Mahaffey
|
6 |
2019 |
6
🐜
|
|
🦁
|
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
10 auth.
Jingwei Li,
B. Neal,
V. Perkovic,
D. de Zeeuw,
B. Neuen,
C. Arnott,
...
R. Simpson,
Richard Oh,
K. Mahaffey,
H. Heerspink
|
6 |
2020 |
6
🦁
|
|
🐜
|
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
11 auth.
J. Januzzi,
Jialin Xu,
Jingwei Li,
Wayne Shaw,
Richard Oh,
M. Pfeifer,
...
J. Butler,
N. Sattar,
K. Mahaffey,
B. Neal,
Michael K. Hansen
|
5 |
2020 |
5
🐜
|
|
🐜
|
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
13 auth.
T. Sen,
Jingwei Li,
B. Neuen,
B. Neal,
C. Arnott,
C. Parikh,
S. Coca,
V. Perkovic,
K. Mahaffey,
Yshai Yavin,
...
N. Rosenthal,
Michael K. Hansen,
Hiddo J. L. Heerspink
|
5 |
2021 |
5
🐜
|
|
🐜
|
Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus
18 auth.
Jiandi Wu,
Haoxiao Zheng,
Xinyue Liu,
Peisong Chen,
Yunlong Zhang,
Jianjin Luo,
Jiang Kuang,
Jingwei Li,
Yu Yang,
Tianyi Ma,
...
Yanhua Yang,
Xiaohui Huang,
Guoquan Liang,
Yunzhao Hu,
Jason H. Y. Wu,
C. Arnott,
W. Mai,
Yuli Huang
|
5 |
2020 |
5
🐜
|
|
🦁
|
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program.
13 auth.
Jingwei Li,
Sunil V Badve,
Zien Zhou,
A. Rodgers,
R. Day,
Richard Oh,
Mary Lee,
V. Perkovic,
D. de Zeeuw,
K. Mahaffey,
...
G. Fulcher,
D. Matthews,
B. Neal
|
5 |
2019 |
5
🦁
|
|
🐜
|
Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
20 auth.
Ashish Sarraju,
Jingwei Li,
C. Cannon,
T. Chang,
R. Agarwal,
G. Bakris,
D. Charytan,
D. de Zeeuw,
T. Greene,
H. Heerspink,
...
A. Levin,
B. Neal,
C. Pollock,
D. Wheeler,
Yshai Yavin,
Hong Zhang,
B. Zinman,
V. Perkovic,
M. Jardine,
K. Mahaffey
|
5 |
2020 |
5
🐜
|
